King's College London

Research portal

Monitoring the efficacy of dendritic cell vaccination by early detection of (99m) Tc-HMPAO-labelled CD4(+) T cells

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)2188-2191
Number of pages4
JournalEuropean Journal of Immunology
Volume44
Issue number7
DOIs
Publication statusPublished - Jul 2014

King's Authors

Abstract

Dendritic cell (DC) vaccines have been used to induce tumour-specific cytotoxic T cells [1]. However, this approach to cancer immunotherapy has had limited success. To be successful, injected DCs need to migrate to the lymph nodes (LNs) where they can stimulate effector T cells [1]. We and others have previously demonstrated by magnetic resonance imaging (MRI) that tumour antigen-pulsed-DCs labelled ex vivo with superparamagnetic iron oxide nanoparticles (SPIO) migrated to the draining LNs and are capable of activating antigen-specific T cells [2, 3]. The results from our study demonstrated that ex vivo SPIO-labelled and OVA-pulsed DCs prime cytotoxic CD8(+) T-cell responses to protect against a B16-OVA tumour challenge. In the clinic, a possible non-invasive surrogate marker for efficacy of DC vaccination is to image the specific migration and accumulation of T cells following DC vaccination.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454